Subsequent Events

6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

8. Subsequent Events

Bio-Path entered into an agreement for drug substance manufacture of development batches of the antisense material for its second drug candidate, Liposomal Bcl-2.  The Company also entered into an agreement with a testing firm for a new drug substance characterization assay.  Bio-Path entered into an agreement with a public relations firm for development and execution of a communications program designed to increase visibility and understanding of, as well as interest in, Bio-Path, its product candidates, business strategy, milestones and people among key stakeholders.  In total, these projects will require Bio-Path to pay approximately $200,000 over a twelve month period.